acute coronary syndrome management rrt
DESCRIPTION
Made by Ranjith R Thampi. This was a powerpoint I had made for a Cardiology Seminar during internship. Got it checked by cardiologists, all approved. Covers management of UA, NSTEMI and STEMI. This was my favorite topic. I think the flowcharts will be clear to the point. Kindly comment and let me know.TRANSCRIPT
![Page 1: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/1.jpg)
Treatmentof
Acute Coronary Syndrome
Ranjith R Thampi
![Page 2: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/2.jpg)
I. Initial evaluation & stabilizationII. Optimized Anti-ischaemic & Anti-platelet therapyIII. Focused cardiac care
OBJECTIVES
![Page 3: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/3.jpg)
Chest pain suggestive of
ischemia
12 lead ECG Obtain Initial
cardiac enzymes FBC,
Electrolytes, Urea, Creatinine, Coagulation Studies
CXR
Immediate assessment within 10 Minutes
Establish diagnosis
Read ECG Identify
complications
Assess for reperfusion
Initial labs
and tests
Emergent care
History &
Physical IV access Cardiac
monitoring Oxygen Nitrates Aspirin
![Page 4: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/4.jpg)
ECG assessment
ST Elevation or new LBBBSTEMI
Non-specific ECGUnstable Angina
ST Depression or dynamicT wave inversions
NSTEMI
![Page 5: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/5.jpg)
UNSTABLE
ANGINA
NSTEMI
![Page 6: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/6.jpg)
![Page 7: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/7.jpg)
![Page 8: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/8.jpg)
General Measures Oxygen and ECG monitoring Oxygen 2-4 L/minPain Relief
5-10mg Morphine iv + 10mg Metoclopramide iv
Control Ischaemia Nitrates- GTN spray or Sublingual Tabs 0.3-0.6 mg/5
mins
i/v Nitroglycerin 10 mg/min -blockers/CCB’s
![Page 9: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/9.jpg)
Therapeutic Goals PREVENT Re-thrombosis & Downstream Embolization Anti-platelet therapy
Aspirin upto 300 mg stat + 75 mg ODClopidogrel 300-600 mg 75 mg ODGlycoprotein IIB/IIIA inhibitors
Anti-coagulant therapyUFH or LMWH LMWH- Inj. Heparin s/c 1mg/kg 12hrlyUFH- Inj. Heparin 5000U i/v bolus + IVI
![Page 10: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/10.jpg)
Therapeutic Goals
Relieve Obstruction
Cardiac catheterizationPercutaneous Coronary Interventions
Coronary Artery Bypass Graft
![Page 11: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/11.jpg)
Based on Risk: (ACS Guidelines 2006)Low Risk: <2 % chance MI or Death within next 6 monthsHigh Risk: >10 % chance of Mortality in 6 months
High Risk:
H E A R T D O C
Unstable Angina/NSTEMI Focused Cardiac Care
![Page 12: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/12.jpg)
Low Risk
![Page 13: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/13.jpg)
UA/NSTEMI High Risk- Very Unstable
-Consider adding GP IIb/IIIa inhibitors (along with aspirin, clopidogrel and heparin)
-Urgent/ Immediate Cardiac Catheterization (<24 hrs) after starting UFH i/v-Consider use of Intra-Aortic Balloon Pump to stabilize patient prior to coronary angiography
![Page 14: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/14.jpg)
![Page 15: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/15.jpg)
![Page 16: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/16.jpg)
![Page 17: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/17.jpg)
![Page 18: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/18.jpg)
![Page 19: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/19.jpg)
![Page 20: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/20.jpg)
![Page 21: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/21.jpg)
Low & High RiskLongterm Therapy
Aspirin 75 mg Daily Clopidogrel 75 mg Daily Atorvastatin 80 mg Ramipril 10 mg Beta Blockade- Metoprolol/Atenolol Glycemic Control Life-style modification
![Page 22: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/22.jpg)
NITRATES NITRATES
Low dose- VenodilatorHigh dose- Arteriolar dilatorReduces Preload/Afterload + MOD
MOA- Acts by releasing NO in vascular smooth muscleInhibits Platelet Aggregation
ADR- Throbbing Headache, Nausea, Dizziness, Hypotension, Reflex Tachycardia,
Tolerance develops over longterm use
C/I- Hypotension, Sildenafil Use(Viagra)
![Page 23: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/23.jpg)
ANTIPLATELETS ASPIRIN
COX inhibitor- TXA2 synthesis by platelets fall Irreversible inhibition of platelet aggregation Stabilize plaque and arrest thrombus
CLOPIDOGREL Irreversible inhibition of platelet aggregation via inhibition of
ADP and fibrinogen by altering surface receptors Used in support of cath / PCI intervention or if unable to take
aspirin Course of 3-12 month duration depending on scenario
*NEWER ANTIPLATELETS Ticagrelor 50,100,200 mg Prasugrel 60 mg bolus + 10 mg (C/I: prior TIA, >75 yrs) i/v Cangrelor 180 mg loading + 90 mg BD
![Page 24: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/24.jpg)
Platelet GP IIb/IIIa Receptor Inhibitors
-Inhibition of platelet aggregation at final common pathway
-Best for PCI, reduces ischemic complicationsADR- Hemorrhage, Thrombocytopenia, Arrhythmias, Constipation
Abciximab..pci Eptifibatide..acs Tirofiban..acs
Only through Parenteral Infusion
![Page 25: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/25.jpg)
![Page 26: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/26.jpg)
ANTICOAGULANTSHEPARIN MOA- Inhibition of Factor Xa and Thrombin
IIa mediated conversion of fibrinogen to fibrin ADR- Bleeding, Hypersensitivity reactions,
Thrombocytopenia(HIT), Osteoporosis, Skin necrosis, Alopecia, Hypoaldosteronism
C/I- Bleeding disorders, SBE, Ocular & Neurosurgery, Chronic alcoholics, Cirrhosis, Renal Failure
![Page 27: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/27.jpg)
HeparinTypes- UFH, LMWH
UFH 60 U/Kg iv bolus + M 16 U/Kg/hrLMWH Enox- 1 mg/Kg s/c Dalte- 120 IU/Kg Fondaparinux (Apixaban, Rivaroxaban) Bivalirudin
BD
![Page 28: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/28.jpg)
![Page 29: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/29.jpg)
Thrombus Formation and Agents Acting
![Page 30: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/30.jpg)
ACE-inhibitors Captopril, Lisinopril , Ramipril, Perindopril MOA- Inhibits A1 pressor action, Reduced Aldosterone, Reduced vasoconstriction, reduced sodium retention Improves LV DysfunctionADR- Hypotension, Hyperkalemia, Dry Cough, Angioedema, Fetopathies, ARFC/I- Renal Failure, Renal Artery StenosisStart early and aim for highest doses Captopril - 50mg TDS, Lisinopril 20mg D, Ramipril 10mg D
![Page 31: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/31.jpg)
Angiotensin Receptor BlockersLosartan, Temisartan, Candesartan, Olmesartan, ValsartanARB as substitute for patients unable to use ACE-I
MOA- AT2 receptor blockadePrevents: Vasoconstriction, sympathetic stimulation, Aldosterone and Adr release from adrenals, Salt & Water reabsorptionADR- Hypotension, Hyperkalemia, Fetopathies
STATINS- Atorvastatin, Simvastatin, Rosuvastatin
MOA- HMG CoA inhibition, blocks hepatic cholesterol synthesis, Increased LDL, VLDL blood clearanceADR- GI disturbances, Myopathies, Myalgia, HeadacheC/I- Liver Disease, Renal Impairment
![Page 32: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/32.jpg)
Beta BlockersAtenolol, Carvedilol, Esmolol, Metoprolol, PindololMOA- Decreases HR, Force of contraction, Cardiac Output, Prolongs Systole, AntiarrhythmicADR- Ppts CHF, Carbohydrate Intolerance, Altered Lipid ProfileC/I- Bradycardia, Reactive airway disease, Sinus Node Dysfunction/AV block, Severe Heart failure*Diltiazem instead
Calcium Channel BlockersAmlodipine, Diltiazem, Nifedipine, Nimodipine, Verapamil
MOA- Smooth muscle relaxation & vasodilationSlows HR, Reduces: afterload, myocardial contractility, MODADR- Accentuates AV Block, CHF*Nifedipine causes abrupt changes in BP and HR occur without appropriate Beta Blockade
C/I- LV Dysfunction, Cardiogenic Shock, Sick Sinus Syndrome, Hepatic impairment
![Page 33: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/33.jpg)
ECG assessment
ST Elevation or new LBBBSTEMI
Non-specific ECGUnstable Angina
ST Depression or dynamicT wave inversions
NSTEMI
![Page 34: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/34.jpg)
STEMI
![Page 35: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/35.jpg)
STEMI
2 situations when it becomes difficult to diagnose STEMI
Chronic or Rate Dependent LBBB Paced Rhythm
![Page 36: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/36.jpg)
ACSClinical Diagnosis
ACSClinical Diagnosis
MONA:Morphine + antiemeticOxygenNitratesAspirin 300 mg statClopidogrel 600 mg stat
MONA:Morphine + antiemeticOxygenNitratesAspirin 300 mg statClopidogrel 600 mg stat
Blood Tests:Troponin at 12 hours after onset of pain, U&E, cholesterol, FBC, coagulationAdmission or subsequent ECG
Blood Tests:Troponin at 12 hours after onset of pain, U&E, cholesterol, FBC, coagulationAdmission or subsequent ECG
STEMI
![Page 37: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/37.jpg)
Immediate Triage
Immediate Triage
12 Lead ECGShowing thrombolyseable
criteria
12 Lead ECGShowing thrombolyseable
criteria
ECG criteria-1 mm ST elevation in at least 2 limb leads-2 mm ST elevation in at least 2 precordial leads
-LBBB with typical clinical presentation
ECG criteria-1 mm ST elevation in at least 2 limb leads-2 mm ST elevation in at least 2 precordial leads
-LBBB with typical clinical presentation
Extra ECG requirements
Inferior ST elevation Do Rpt ECGPosterior changes Deep ST-elevation + tall R waves in V1- V3
Extra ECG requirements
Inferior ST elevation Do Rpt ECGPosterior changes Deep ST-elevation + tall R waves in V1- V3
Definite STEMI
Thrombolysis(if PCI unavailable immediately)
Target < 30 minDoor-needle time in > 75% patients
Thrombolysis(if PCI unavailable immediately)
Target < 30 minDoor-needle time in > 75% patients
Primary PCIPrimary PCI
Repeat ECG 90 min from comencement of lytic Aim: > 50% reduction in peak ST segment elevation
Repeat ECG 90 min from comencement of lytic Aim: > 50% reduction in peak ST segment elevation
Tenectoplase (TKN-tPA)Drug of choice with LMWH for pts <75 yrs independent of site
of infarctStreptokinase (SK)
Consider for pts > 75 yrs due to lower incidence of ICH
Tenectoplase (TKN-tPA)Drug of choice with LMWH for pts <75 yrs independent of site
of infarctStreptokinase (SK)
Consider for pts > 75 yrs due to lower incidence of ICH
Ix on admissionU&E, FBC, Cholest, coagulation
Repeat12 hrs Troponin, ECGControl RBS
Ix on admissionU&E, FBC, Cholest, coagulation
Repeat12 hrs Troponin, ECGControl RBS
![Page 38: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/38.jpg)
Risk assessment & secondary preventionAspirin StatinEarly beta blockade Ace- inhibitorsAngiogram Pre discharge RehablitationConsider patient’s pre morbid state & suitability for revascularisation
Risk assessment & secondary preventionAspirin StatinEarly beta blockade Ace- inhibitorsAngiogram Pre discharge RehablitationConsider patient’s pre morbid state & suitability for revascularisation
REASSESS
Failed Reperfusion
Haemodynamics compromiseContinuing pain
Discuss suitability for rescue PCI
Failed Reperfusion
Haemodynamics compromiseContinuing pain
Discuss suitability for rescue PCI
![Page 39: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/39.jpg)
Primary PCI Usually done under anticoagulant
cover Coronary recanalization is done with Angioplasty and commonly Stenting Best D2B Time- <90 mins
THROMBOLYSIS Lyses fibrin thrombi and reduces
clot-caused infarct size allowing reperfusion D2N Time- <30 minsBest Time- Upto 12 hrs from Onset of symptoms
![Page 40: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/40.jpg)
THROMBOLYSIS Streptokinase & Urokinase[1.5 MU in 100 ml NS
ivi/1 hr]S/E: Nausea, Vomiting, Haemorrhage, Stroke
Tenectaplase [0.5 mg/Kg over 10 seconds]Bolus Injection best for paramedicsIndication: Ant. Wall MI, Previous SK useSBP< 100 mm Hg, New LBBB
Alteplase Reteplase[2 iv boluses 2hrs apart]
[10 MU bolus/2mins + 10 MU bolus after 30 mins]*Patients with STEMI who have not received reperfusion therapy should be treated with fondaparinux immediately
![Page 41: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/41.jpg)
Thrombus Formation and Agents Acting
![Page 42: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/42.jpg)
THROMBOLYSIS
ECG is done after 1 hr and assessed: Successful Thrombolysis
-Reperfusion Arrhythmias(Accelerated idioventricular rhythm)-Persistent Ventricular ectopics-Alleviation of chest pain
Failed Thrombolysis- Uncontrolled pain(Persistent Angina)- Continuing ST- elevation- Absent VTc, Absent Idioventricular arrhythmias
Consider re-thrombolysis with rt-PA, Tenecteplase, Rescue PCI
![Page 43: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/43.jpg)
ABSOLUTE Active GI Bleed Aortic Dissection Previous ICH Stroke<2 months Intracranial
aneurysm/ neoplasm Head injury<2
months Pericarditis Pancreatitis Warfarin/INR>3
ABSOLUTE Active GI Bleed Aortic Dissection Previous ICH Stroke<2 months Intracranial
aneurysm/ neoplasm Head injury<2
months Pericarditis Pancreatitis Warfarin/INR>3
RELATIVE Traumatic CPR Surgery<10 days Arterial Puncture<24
hrs SBP>180 Bleeding Tendency Trauma Pregnancy Bacterial Endocarditis
RELATIVE Traumatic CPR Surgery<10 days Arterial Puncture<24
hrs SBP>180 Bleeding Tendency Trauma Pregnancy Bacterial Endocarditis
Contraindications vary slightly between thrombolytics
Contraindications to thrombolysis
![Page 44: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/44.jpg)
Primary PCI
Current primary PCI strategy: Initiate Glycoprotein IIb/IIIa inhibitor in ED, together with Aspirin+Heparin, followed by rapid application of coronary angioplasty with stenting
Operator and institutional experience is an issue more important to outcomes with primary PCI than fibrinolysis.
![Page 45: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/45.jpg)
Primary PCIFacilitated PCI Facilitated PCI is the use of
pharmacological reperfusion treatment delivered prior to a planned PCI. *There is no evidence of a significant clinical benefit and so facilitated PCI is currently not recommended.
![Page 46: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/46.jpg)
Primary PCI
Rescue PCIPerformed on a coronary artery which remains occluded despite fibrinolytic therapy. *Associated with significant reduction in heart failure & reinfarction
Indication:-Evidence of failed fibrinolysis based on clinical signs and insufficient ST-segment resolution-Clinical or ECG evidence of a large infarct-If can be performed <12 hours after the onset of symptoms.
![Page 47: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/47.jpg)
Primary PCI Preferred When:
-Diagnosis in doubt-Cardiogenic Shock-Increased Bleeding-Symptoms for 2-3 hrs, clot more mature, less chance for lysis
DISADVANTAGES:-Cost-Trained Personnel-Facilities
![Page 48: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/48.jpg)
COMPLICATIONS
![Page 49: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/49.jpg)
Complications ISCHAEMIC- Angina, Reinfarction,
Infarct Extension MECHANICAL- LVD, Cardiogenic
Shock, CHF, MV Dysfunction, Aneurysm, Cardiac Rupture
ARRHYTHMIAS- Atrial, Ventricular, SA/AV Node Dysfunction
THROMBOSIS & EMBOLIC- CNS, Peripheral embolisation, Pericarditis
PSYCHOSOCIAL- Depression *Dressler’s Syndrome
![Page 50: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/50.jpg)
![Page 51: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/51.jpg)
Admit to CCU & Monitor closely
O2 2-4 L, aim for SaO2 >95%
ANALGESIA2.5-5mg Morphine iv+ 10mg
Metoclopramide iv
INVESTIGATIONS and close monitoring
Correct arrhythmias, U&E abnormalities or acid-base
disturbance
Optimize filling pressure,if available, measure Pulmonary Capillary Wedge
Pressure(PCWP)
Pulmonary edema+
Cardiogenic Shock
KILLIP Class 3+4 Treatmen
t
![Page 52: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/52.jpg)
PCWP
Plasma Expander 100mL every 15 mins iv
Aim for PCWP of 15-20 mm Hg
Consider ‘renal dose’ dopamine 2-5 mg/kg/min iv initially(via central line
only)
Consider intra-aortic balloon pump if expecting condition to improve, or time is required while
awaiting surgery
PCWP <15 mm Hg fluid load
PCWP >15 mm Hg
Inotropic supporteg: Dobutamine 2.5-10
mg/kg/min iviAim for SBP >80 mm Hg
Look for and treat any reversible cause:MI or PE- Consider Thrombolysis;
Surgery for: a/c VSD, MR, AR
![Page 53: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/53.jpg)
![Page 54: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/54.jpg)
Why Thrombolyse only STEMI?
UA/ NSTEMI- Plaque stabilization to prevent progression of disease is required. More risk of bleeding complications.In UA/NSTEMI Obstruction is caused by plaque(platelet-rich)In STEMIObstruction is by Thrombus
![Page 55: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/55.jpg)
Prevention
![Page 56: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/56.jpg)
Secondary Prevention
Comorbid Diseases HTN, DM, Dyslipidemia
Behavioral smoking, diet, physical activity,
weight redn
Cognitive Education, cardiac rehab program
![Page 57: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/57.jpg)
Secondary PreventionComorbid Disease
management Blood Pressure Goals < 140/90 or <130/80 in DM
/CKD Maximize use of beta-blockers & ACE-I
Lipids LDL < 100 mg/dl ; TG < 200 mg/dl Maximize use of statins; consider
fibrates/niacin first line for TG>500; consider omega-3 fatty acids
Diabetes HbA1c < 7%
![Page 58: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/58.jpg)
Secondary preventionBehavioral intervention
Smoking cessation Cessation-class, meds, counseling
Physical Activity Goal 30 - 60 minutes daily Risk assessment prior to initiation
Diet Fiber diet, omega-3 fatty acids <7% total calories from saturated
fats
![Page 59: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/59.jpg)
Medication Checklist after ACS
Antiplatelet agent Aspirin* and/or Clopidorgrel GP Inhibitors*
Lipid lowering agent Statins* Fibrate / Niacin / Omega-3 FAs
Antischaemic & LV remodelling Prevention Beta blocker* ACE-I*/ARB Aldactone (as appropriate)
![Page 60: Acute Coronary Syndrome Management RRT](https://reader034.vdocuments.mx/reader034/viewer/2022052212/554b25bab4c905ce088b46b4/html5/thumbnails/60.jpg)
Thank You